
Commentary|Podcasts|July 15, 2025
COBRRA Trial Results Raise Questions About VTE Management
The COBBRA trial compared bleeding risk with rivaroxaban vs apixaban in patients with acute venous thromboembolism.
Advertisement
This week, host Craig Beavers sat down with Tara Lech, PharmD, CACP, director of anticoagulation services at Beth Israel Lahey Health, to discuss recent findings from the COBBRA trial, which compared bleeding risk with rivaroxaban vs apixaban in patients with acute venous thromboembolism.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
2
mRNA COVID-19 Booster Outperforms Protein-Based Shot on Antibodies, But Both Cut Infections Over 12 Months
3
Up to 5 Cups of Coffee Daily Safe—and Benficial—for Most Adults
4
Pharmacist Outreach Doubles SGLT2 Inhibitor Uptake in CKD
5





































































































